The Global, Regional, and National Burden of Stomach Cancer in 195 Countries, 1990–2017: a Systematic Analysis for the Global Burden of Disease Study 2017

Arash Etemadi,Saeid Safiri,Sadaf G. Sepanlou,Kevin Ikuta,Catherine Bisignano,Ramin Shakeri,Mohammad Amani,Christina Fitzmaurice,Molly R. Nixon,Nooshin Abbasi,Hassan Abolhassani,Shailesh M. Advani,Mohsen Afarideh,Tomi Akinyemiju,Tahiya Alam,Mahtab Alikhani,Vahid Alipour,Christine A. Allen,Amir Almasi-Hashiani,Jalal Arabloo,Reza Assadi,Suleman Atique,Ashish Awasthi,Ahad Bakhtiari,Masoud Behzadifar,Kidanemaryam Berhe,Neeraj Bhala,Ali Bijani,Muhammad Shahdaat Bin Sayeed,Tone Bjorge,Antonio M. Borzi,Dejana Braithwaite,Hermann Brenner,Giulia Carreras,Felix Carvalho,Carlos A. Castaneda-Orjuela,Franz Castro,Dinh-Toi Chu,Vera M. Costa,Ahmad Daryani,Dragos Virgil Davitoiu,Gebre T. Demoz,Asmamaw Bizuneh Demis,Edgar Denova-Gutierrez,Subhojit Dey,Mostafa Dianati Nasab,Shirin Djalalinia,Mohammad Hassan Emamian,Mohammad Farahmand,Joao C. Fernandes,Florian Fischer,Masoud Foroutan,Mohamed M. Gad,Silvano Gallus,Gebreamlak Gebremedhn Gebremeskel,Getnet Azeze Gedefew,Fatemeh Ghaseni-Kebria,Giuseppe Gorini,Nima Hafezi-Nejad,Arvin Haj-Mirzaian,Josep M. Haro,James D. Harvey,Amir Hasanzadeh,Maryam Hashemian,Hamid Y. Hassen,Simon Hay,Hagos D. Hidru,Mihaela Hostiuc,Mowafa Househ,Olayinka Stephen Ilesanmi,Milena D. Ilic,Kaire Innos,Farhad Islami,Spencer L. James,Ensiyeh Jenabi,Rohollah Kalhor,Farin Kamangar,Amir Kasaeian,Andre Pascal Kengne,Yousef Saleh Khader,Rovshan Khalilov,Ejaz Ahmad Khan,Gulfaraz Khan,Maryam Khayamzadeh,Maryam Khazaee-Pool,Salman Khazaei,Abdullah T. Khoja,Fatemeh Khosravi Shadmani,Yun Jin Kim,Jonathan M. Kocarnik,Hamidreza Komaki,Ai Koyanagi,Vivek Kumar,Carlo La Vecchia,Alan D. Lopez,Raimundas Lunevicius,Navid Manafi,Ana-Laura Manda,Birhanu Geta,Hailemariam Meheretu,Getnet Mengistu,Bartosz Miazgowski,Seyed Mostafa Mir,Karzan Abdulmuhsin Mohammad,Naser Mohammad Gholi Mezerji,Mahdi Mohammadian,Abdollah Mohammadian-Hafshejani,Reza Mohammadpourhodki,Shafiu Mohammed,Farnam Mohebi,Ali H. Mokdad,Lorenzo Monasta,Mahmood Moosazadeh,Maryam Moossavi,Ghobad Moradi,Farhad Moradpour,Rahmatollah Moradzadeh,Ilais Moreno Velasquez,Abbas Mosapour,Mehdi Naderi,Gurudatta Naik,Farid Najafi,Azin Nahvijou,Ionut Negoi,Rajan Nikbakhsh,Marzieh Nojomi,Andrew T. Olagunju,Tinuke O. Olagunju,Eyal Oren,Hadi Parsian,Cristiano Piccinelli,Akram Pourshams,Hossein Poustchi,Navid Rabiee,Amir Radfar,Alireza Rafiei,Mahdi Rahimi,Marveh Rahmati,Andre M. N. Renzaho,Nima Rezaei,Ana Isabel Ribeiro,Gholamreza Roshandel,Anas M. Saad,Seyedmohammad Saadatagah,Hamideh Salimzadeh,Abdallah M. Samy,Juan Sanabria,Milena M. Santric Milicevic,Arash Sarveazad,Monika Sawhney,Faramarz Shaahmadi,Mario Sekerija,Masood Ali Shaikh,Amir Shamshirian,Sudeep K. Siddappa Malleshappa,Jasvinder A. Singh,Catalin-Gabriel Smarandache,Moslem Soofi,Takahiro Tabuchi,Bahrey,Leili Tapak,Berhe Etsay Tesfay,Eugenio Traini,Bach Tran,Khanh Bao Tran,Marco Vacante,Amir Vahedian-Azimi,Yousef Veisani,Kia Vosoughi,Isidora S. Vujcic,Ronny Westerman,Adam Belay Wondmieneh,Rixing Xu,Sanni Yaya,Vahid Yazdi-Feyzabadi,Zabihollah Yousefi,Bhaman Yousefi,Telma Zahirian Moghadam,Leila Zaki,Mohammad Zamani,Maryam Zamanian,Hamed Zandian,Afshin Zarghi,Zhi-Jiang Zhang,Mohsen Naghavi,Reza Malekzadeh

DOI: https://doi.org/10.1016/s2468-1253(19)30328-0

2020-01-01

Abstract:BackgroundThe burden of inflammatory bowel disease (IBD) is rising globally, with substantial variation in levels and trends of disease in different countries and regions.Understanding these geographical differences is crucial for formulating effective strategies for preventing and treating IBD.We report the prevalence, mortality, and overall burden of IBD in 195 countries and territories between 1990 and 2017, based on data from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2017. MethodsWe modelled mortality due to IBD using a standard Cause of Death Ensemble model including data mainly from vital registrations.To estimate the non-fatal burden, we used data presented in primary studies, hospital discharges, and claims data, and used DisMod-MR 2.1, a Bayesian meta-regression tool, to ensure consistency between measures.Mortality, prevalence, years of life lost (YLLs) due to premature death, years lived with disability (YLDs), and disability-adjusted life-years (DALYs) were estimated.All of the estimates were reported as numbers and rates per 100 000 population, with 95% uncertainty intervals (UI). FindingsIn 2017, there were 6•8 million (95% UI 6•4-7•3) cases of IBD globally.The age-standardised prevalence rate increased from 79•5 (75•9-83•5) per 100 000 population in 1990 to 84•3 (79•2-89•9) per 100 000 population in 2017.The age-standardised death rate decreased from 0•61 (0•55-0•69) per 100 000 population in 1990 to 0•51 (0•42-0•54) per 100 000 population in 2017.At the GBD regional level, the highest age-standardised prevalence rate in 2017 occurred in high-income North America (422•0 [398•7-446•1] per 100 000) and the lowest agestandardised prevalence rates were observed in the Caribbean (6•7 [6•3-7•2] per 100 000 population).High Sociodemographic Index (SDI) locations had the highest age-standardised prevalence rate, while low SDI regions had the lowest age-standardised prevalence rate.At the national level, the USA had the highest age-standardised prevalence rate (464•5 [438•6-490•9] per 100 000 population), followed by the UK (449•6 [420•6-481•6] per 100 000).Vanuatu had the highest age-standardised death rate in 2017 (1•8 [0•8-3•2] per 100 000 population) and Singapore had the lowest (0•08 [0•06-0•14] per 100 000 population).The total YLDs attributed to IBD almost doubled over the study period, from 0•56 million (0•39-0•77) in 1990 to 1•02 million (0•71-1•38) in 2017.The agestandardised rate of DALYs decreased from 26•5 (21•0-33•0) per 100 000 population in 1990 to 23•2 (19•1-27•8) per 100 000 population in 2017.Interpretation The prevalence of IBD increased substantially in many regions from 1990 to 2017, which might pose a substantial social and economic burden on governments and health systems in the coming years.Our findings can be useful for policy makers developing strategies to tackle IBD, including the education of specialised personnel to address the burden of this complex disease.